These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The successful conversion to Tacrolimus (FK506) of a renal transplant recipient with cyclosporin-induced haemolytic-uraemic syndrome. Richardson D; Jones CH; Newstead CG; Will EJ; Lodge JP Nephrol Dial Transplant; 1996 Dec; 11(12):2498-500. PubMed ID: 9017633 [No Abstract] [Full Text] [Related]
4. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278 [TBL] [Abstract][Full Text] [Related]
5. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. McCauley J; Bronsther O; Fung J; Todo S; Starzl TE Lancet; 1989 Dec 23-30; 2(8678-8679):1516. PubMed ID: 2481200 [No Abstract] [Full Text] [Related]
6. Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient. Kiykim AA; Ozer C; Yildiz A; Tiftik N; Senli M; Kelebek E; Doruk E; Akbay E Nephrol Dial Transplant; 2004 Oct; 19(10):2653-6. PubMed ID: 15388824 [No Abstract] [Full Text] [Related]
7. Eye Movement Disorders Following Allogeneic Bone Marrow Transplantation on FK506 (Tacrolimus) and Ganciclovir. Karagun BS; Akbas T; Arpaci T; Antmen B J Pediatr Hematol Oncol; 2018 Jan; 40(1):71-73. PubMed ID: 28731920 [TBL] [Abstract][Full Text] [Related]